Bionano Genomics, Inc.

Good day and welcome to the BioNano fourth quarter and full year 2025 earnings conference call. Today's conference is being recorded. At this time, I would like to turn the conference over to Webb Campbell from Gilmanton Group. Please go ahead.

Thank you, Carmen, and good afternoon, everyone. Welcome to BioNano's fourth quarter and full year 2025 financial results conference call. On the call today is Dr. Eric Homlin, CEO and Principal Financial Officer of BioNano, and Mark Adamczyk, BioNano's Vice President of Accounting and Principal Accounting Officer. After market closed today, BioNano issued a press release announcing its financial results for the fourth quarter and full year 2025. A copy of the press release can be found on the investor relations page of the company's websites. Certain statements made during this conference call may be forward-looking statements Actual results may differ materially from such statements due to several factors and risks, some of which are identified in BioNano's press release and BioNano's report filed with the SEC. These forward-looking statements are based on information available to BioNano today, March 23, 2026, and the company assumes no obligation to update statements as circumstances change. During our call, we may reference certain non-GAAP financial measures, which we believe provide useful information for investors. Reconciliations of these measures to GAAP can be found in our press release and slide deck. An audio recording and webcast replay of today's conference call will also be available online on the investor relations page of the company's website. With that, I will turn the call over to Eric.

Thank you, Webb, and good afternoon, everyone. I'm excited to share our fourth quarter and full year 2025 results with you today, as well as to provide you with our expectations for 2026. I want to begin, however, with the context of the broader space we're aiming to impact, namely pathology, which is the discipline that investigates the causes, developments, and effects of disease. Our products and solutions are focused on transforming pathology from tedious, slow, costly, and labor-intense analog workflows of the past towards streamlined workflows of a digital future defined by technology and platform consolidation, automation, and powerful AI-driven software. Our work in 2025, including the hundreds of publications and presentations by our users, demonstrated meaningful progress toward this goal and the significant value represented by this opportunity. As part of today's call, I want to take time to review the strategy we began implementing in September of 2024, our progress in 2025, and summarize key takeaways from a deep dive into our customer base, revealing the composition of our most profitable customer profile. First, however, I want to ask Mark Adamczak our principal accounting officer, to review our Q4 and 2025 financial highlights. Mark?